Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the earnings power, the dividend and the pipeline still justify stepping in before the earnings report.
Johnson & Johnson walked into 2026 with clear acceleration. Q1 revenue hit $24.06 billion, up 9.9% year over year, and adjusted EPS of $2.70 marked the fourth consecutive beat. Innovative Medicine grew 11.2% even with STELARA down 59.7%, because TREMFYA jumped 68.3%, DARZALEX rose 22.5% and CARVYKTI surged 62.1%. Management raised full-year guidance to $100.30B to $101.30B in revenue and $11.45 to $11.65 in adjusted EPS, and CEO Joaquin Duato told investors JNJ is “delivering on its promise for a year of accelerated growth and impact.”
The Income Case Writes Itself
Dividend Kings do not go on sale often. JNJ has now raised its payout for 64 consecutive years, with the most recent hike of 3.1% pushing the quarterly to $1.34 per share. Backing that check is $19.7 billion in FY2025 free cash flow and $26.80 billion in net income, which grew 90.56%. This is durable retirement income at scale, and a $634.06 billion balance sheet backing it up.
The Catalyst Is Priced, but Not Fully
Polymarket traders are pricing a 92% probability that JNJ beats its Q2 number on July 15, with MedTech carrying an 88% probability of clearing $8.8 billion. Beyond the earnings report, the pipeline offers real optionality: ICOTYDE FDA approval, the TECVAYLI + DARZALEX FASPRO combo, and the planned DePuy Synthes orthopaedics separation that unclutters the multiple. Wall Street is aligned: 15 Buy ratings against just one Sell rating.
Why JNJ Beats the Obvious Alternatives
Compare this to AbbVie (NYSE:ABBV), which is still absorbing Humira biosimilar erosion with a far less diversified base. JNJ neutralizes its own STELARA erosion inside a single segment while also running an $8.64 billion MedTech business that grew 7.7%, something AbbVie cannot match. Pfizer (NYSE:PFE) offers a bigger stated yield but slower top-line growth and weaker pipeline momentum, and it lacks JNJ’s path to double-digit growth by decade’s end. Diversification plus acceleration beats concentration plus decline every time.
The setup heading into July 15 favors owners who already had conviction, with compounding doing the heavy lifting from here.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks